No Evidence to Suggest Medicinal Cannabis Is Effective for Depression, Anxiety or PTSD, Says Systematic Review

Why It Matters

The study challenges the growing off‑label use of therapeutic cannabinoids for mental health, urging clinicians and regulators to reassess prescribing practices and protect patients from ineffective or harmful treatments.

Key Takeaways

• 54 RCTs (1980‑2025) show no mental health benefit.
• Cannabis may aid epilepsy, MS spasticity, pain, but not depression.
• Potential harm: increased psychosis risk, delayed effective treatments.
• Effective for cannabis‑use disorder when combined with therapy.
• Raises calls for stricter prescribing regulations.

Pulse Analysis

The new Lancet Psychiatry meta‑analysis represents the most comprehensive assessment of cannabinoids in mental health to date, aggregating data from 54 randomized trials spanning four and a half decades. While public interest in medicinal cannabis has surged—27% of adults in the U.S. and Canada report using it for health reasons—the review underscores a stark evidence gap for depression, anxiety and PTSD. By systematically evaluating trial quality and outcomes, the study provides a data‑driven counterpoint to anecdotal claims that have fueled rapid market expansion.

Clinicians now face a clearer mandate: prioritize evidence‑based interventions over unproven cannabinoid therapies. The review flags potential adverse effects, including heightened psychosis risk and delayed initiation of proven antidepressants or psychotherapy. Conversely, it confirms modest efficacy for specific indications such as seizure reduction in epilepsy, spasticity in multiple sclerosis, and adjunctive treatment of cannabis‑use disorder when paired with behavioral therapy. These nuanced findings compel medical societies and insurers to refine guidelines, ensuring that prescribing aligns with robust clinical data rather than hype.

Looking ahead, the authors call for tighter regulatory oversight and more rigorous, condition‑specific trials to resolve lingering uncertainties. Policymakers may consider tighter prescribing controls, mandatory counseling, and post‑market surveillance to mitigate misuse. For investors and industry stakeholders, the study signals a potential shift in demand, steering resources toward formulations with demonstrable therapeutic value while curbing growth in poorly supported mental‑health applications. Ultimately, the review reinforces the principle that patient safety and efficacy must drive the evolution of the medicinal cannabis market.